From the Research
Dosage Information
- There is no information available on the dosage of Manjuro in the provided studies 1, 2, 3, 4, 5.
- The studies primarily focus on Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, and its dosage for the treatment of type 2 diabetes.
- The dosage of Tirzepatide mentioned in the studies includes 5 mg, 10 mg, and 15 mg per week 2, 3, 4.
- However, since Manjuro is not mentioned in the studies, there is no relevant information available on its dosage.